So much fun discussing medicine with two of my favorite people in the bronchiectasis world! We will be taking a deep dive into the clinical practice guidelines for Bronchiectasis and how the landscape is rapidly changing. Come join us! @ProfJDChalmers @ATS_PITB #bronchiectasis

🌲2 days to go! 🚨Join us for a discussion on bronchiectasis management with Drs. James D. Chalmers & Timothy Aksamit, covering the ERS & CHEST guidelines. ⭐️Case presented by Emma Johnson ⭐️Moderated by Dr. Divya Reddy @direddy @ProfJDChalmers thoracic.zoom.us/webinar/reg…

Come on thursday to hear the AMAZING Emma Johnson, Me and Tim Aksamit talk about state of the art management of bronchiectasis Chaired by the awesome Divya Reddy Team bronchiectasis @ATS_PITB

🌺 The next chapter in NTM lung disease is being written in the Pacific! Join the NTM & bronchiectasis community in Honolulu for the HAPA NTM & Bronchiectasis Conference. 📅 March 8–10, 2027 📍 Honolulu, Hawaiʻi 🔗 NTMHawaii.org

🚨 Mark your calendars for our next 🌲PINE🌲 Webinar! 🫁 Bronchiectasis Management Reimagined: Key Updates from the 2025 ERS Guidelines Case-based discussion with global experts 🌍 🗓️ Sep 17 |⏱️ 11 AM ET 📝 Register here: thoracic.zoom.us/webinar/reg… @ATS_Assemblies @EuroRespSoc

🗞️ Check out our August PI-TB Newsletter! 🫁🦠 Catch up on the latest infection-related ATS articles, upcoming deadlines and events, Assembly updates, and more. craftprd1.blob.core.windows.…

ERJ Open Research: In MAHALE, benralizumab did not improve bronchiectasis clinical outcomes. Adequately powered randomised trials are needed in the population of interest. bit.ly/4dFjR40

🫁A CAP wish-list: top research priorities from the CAP Research Priority Setting Partnership (PSP) sciencedirect.com/science/ar…

🫁In 310 adults hospitalized with Legionella pneumonia, each 6-hour delay to Legionella-active therapy was associated with 11% higher adjusted odds of 90-day mortality. Median time to effective therapy was significantly longer in immunocompromised hosts 🫁 academic.oup.com/annalsats/a…

🦠New prospective data challenge the assumption that post-TB lung disease is limited to pulmonary TB: adults successfully treated for extrapulmonary TB had persistent spirometric impairment and respiratory symptoms for 1.5 years. 🫁 academic.oup.com/ajrccm/arti…

From #AnnalsATS: Among critically ill adults undergoing BAL for suspected pneumonia, clinical assessment alone often disagreed with BAL-informed adjudication, with overdiagnosis slightly more common than missed pneumonia. academic.oup.com/annalsats/a…

Post-tuberculosis lung disease in treated extra-pulmonary tuberculosis Not just post-TB: extra-pulmonary tuberculosis cases can have lasting lung impairment after treatment. Expanding post-TB screening is critical doi.org/10.1093/ajrccm/aamag… @atscommunity

🥳Happy Friday! A fun case of a rare pulmonary complication following fungal infections. Would you have guessed? doi.org/10.1093/annalsats/aa… #pulmonary #ATS @AnnalsATS @atscommunity

🫁 Not all post-TB lung disease is biologically the same. Distinct transcriptomic signatures in restrictive vs. obstructive post-TB lung disease—could this enable more precise therapies? doi.org/10.1093/ajrccm/aamag… #tuberculosis #pulmonary #ATS @atscommunity

The American Thoracic Society (ATS) strongly opposes the White House’s new executive order affecting federal childhood vaccine policy. “This action is not grounded in scientific evidence and risks further eroding public confidence in the safety of routinely recommended childhood immunizations. The executive order directly affects prevention of influenza, COVID-19, and RSV, respiratory infections that can cause severe illness, hospitalization, respiratory failure, and death, particularly among children with underlying lung disease or other medical vulnerabilities. The order will result in delays, lower vaccination rates among U.S. children, and more disease outbreaks.” - Tina Hartert, MD, MPH, co-chair, ATS Vaccine Initiative Advisory Panel. The ATS will continue to advocate for evidence-based, public health-focused approach to childhood vaccination policy.

📢 Know a colleague who would be a great Assembly leader? Nominate them for a leadership position! 🗓️ Deadline: September 4 👉 surveymonkey.com/r/KQHMZL8?u…

🫁 Precision medicine for pneumonia: can we specifically target the host, not just the pathogen? New AJRCCM research identifies 7 histopathologic subphenotypes, offering a framework for host-directed therapies. doi.org/10.1093/ajrccm/aamag… #pneumonia #pulmonary #ATS @atscommunity

Assembly Leadership Nominations 2027-28 Program Committee Chair-Elect to serve as Program Committee Chair-Elect in 2027-2028. Open for ALL Assemblies, 2027-2028 Nominating Committee Members, 2 members will be elected. Open for ALL Assemblies. learn more: shorturl.at/cWNKF

New #BMJResearch: Evaluation of patient centred digital adherence technology for tuberculosis treatment outcomes bit.ly/4wjH29Q Plus commentary bit.ly/3THctxb

🔥Biggest driver of severe pneumonia? You all voted "excess inflammation"—by a landslide. Can we target it? New research explores macrophage membrane-coated nanoparticles to dampen inflammation in severe bacterial pneumonia. doi.org/10.1093/ajrccm/aamag… #pneumonia #pulmonary #ATS